Income Statement

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

AstraZeneca PLC, consolidated income statement

US$ in millions

12 months ended:	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010
Revenue	26,095)	25,711)	27,973)	33,591)	33,269)
Cost of sales	(5,842)	(5,261)	(5,393)	(6,026)	(6,389)
Gross profit	20,253)	20,450)	22,580)	27,565)	26,880)
Distribution costs	(324)	(306)	(320)	(346)	(335)
Research and development expense	(5,579)	(4,821)	(5,243)	(5,523)	(5,318)
Selling, general and administrative costs	(13,000)	(12,206)	(9,839)	(11,161)	(10,445)
Profit on disposal of subsidiary	—)	—)	—)	1,483)	—)
Royalties	374)	464)	567)	559)	340)
Impairment	(18)	—)	—)	—)	—)
Net gain (loss) on disposal of non-current assets	(235)	13)	8)	33)	66)
Gains on disposal of product rights	285)	20)	255)	—)	—)
Net loss on disposal of other intangible assets	—)	—)	—)	—)	(1)
Other income	381)	120)	140)	226)	307)
Other expense	—)	(22)	—)	(41)	—)
Other operating income and expense	787)	595)	970)	777)	712)
Operating profit	2,137)	3,712)	8,148)	12,795)	11,494)
Returns on fixed deposits and equity securities	10)	9)	18)	9)	9)
Returns on short-term deposits	23)	23)	24)	37)	33)
Expected return on post-employment defined benefit plan assets	—)	—)	486)	502)	451)
Fair value gains on debt, interest rate swaps and investments	16)	18)	—)	4)	23)
Net exchange gains	29)	—)	—)	—)	—)
Finance income	78)	50)	528)	552)	516)
Interest on debt and commercial paper	(383)	(388)	(404)	(404)	(450)
Interest on overdrafts, finance leases and other financing costs	(35)	(25)	(22)	(29)	(29)
Net interest on post-employment defined benefit plan net liabilities	(92)	(79)	(507)	(539)	(543)
Fair value charges on debt, interest rate swaps and investments	—)	—)	(10)	—)	—)
Net exchange losses	—)	(3)	(15)	(8)	(11)
Discount unwind on contingent consideration arising on business combinations	(391)	—)	—)	—)	—)
Discount unwind on other long-term liabilities	(62)	—)	—)	—)	—)
Finance expense	(963)	(495)	(958)	(980)	(1,033)
Share of after tax losses in joint ventures	(6)	—)	—)	—)	—)
Profit before tax	1,246)	3,267)	7,718)	12,367)	10,977)
Taxation	(11)	(696)	(1,391)	(2,351)	(2,896)
Profit for the period	1,235)	2,571)	6,327)	10,016)	8,081)
Profit attributable to non-controlling interests	(2)	(15)	(30)	(33)	(28)
Profit attributable to owners of the Parent	1,233)	2,556)	6,297)	9,983)	8,053)

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Download chart

Income statement item	Description	The company
Revenue	Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.	AstraZeneca PLC revenue decreased from 2012 to 2013 but then slightly increased from 2013 to 2014.
Operating profit	The net result for the period of deducting operating expenses from operating revenues.	AstraZeneca PLC operating profit decreased from 2012 to 2013 and from 2013 to 2014.
Profit before tax	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	AstraZeneca PLC profit before tax decreased from 2012 to 2013 and from 2013 to 2014.
Profit attributable to owners of the Parent	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	AstraZeneca PLC profit attributable to owners of the Parent decreased from 2012 to 2013 and from 2013 to 2014.

AstraZeneca PLC (NYSE:AZN)

Income Statement